MDXH MDXHEALTH

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – February 12, 2026 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026.

Title:



Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results and

Corporate Update Conference Call and Webcast
Date:February 26, 2026
Time:4:30pm ET/ 22:30 CET
Conference Call Dial-in Details:



United States: 1-844-825-9789

Int’l: 1-412-317-5180

Belgium: 0800 38 961

United Kingdom: 0800 279 9489







Conference ID:        10206764
Webcast:

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation), exosomal and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

LifeSci Advisors (IR & PR)

John Fraunces

Managing Director

Tel:

Attachment



EN
12/02/2026

Underlying

MDXHMDXHEALTH

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDXHEALTH

Guy Sips ... (+2)
  • Guy Sips
  • Mathijs Geerts Danau
BTLS BIOTALYS NV
MDXH MDXHEALTH
03/17/26 March 17, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
MDXH MDXHEALTH

mdxhealth Data from the ProMPT study shows predictive value of GPS tes...

At EAU 2026, mdxhealth presented data from Oxford's ProMPT study, demonstrating that the GPS test successfully stratifies the risk of treatment failure across treatment cohorts. The results showed high six-year freedom-from-failure rates. Mdxhealth and Oxford will continue their collaboration through the recently initiated ProtecT-GPS study, with management expecting data read-outs in 2026/2027. We believe these data could support future market share gains for GPS mdx and could help expand the m...

03/17/26 March 17, 2026 1 EN
 PRESS RELEASE
Free
MDXH MDXHEALTH

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the...

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – March 16, 2026 () – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that new data demonstrating the prognostic value of the Genomic Prostate Sco...

March 16, 2026 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
PROX Proximus SA de ...
MTLS MATERIALISE ADS ... (+8)

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

PROX PROXIMUS SA DE DROIT PUBLIC
MTLS MATERIALISE ADS
FAGR FAGRON SA
TERB TER BEKE N.V.
REC RECTICEL SA
ACKB ACKERMANS & VAN HAAREN NV
FUR FUGRO NV
MDXH MDXHEALTH
02/27/26 February 27, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
MDXH MDXHEALTH

mdxhealth FY25 revenues slightly below preliminary figures but guidanc...

mdxhealth's 4Q25 revenues come in $ 1m lower than the preliminary revenue figures shared in January ($ 30.5m). However the company maintains FY26 revenue guidance of $ 137-140m, implying 27-30% year-over-year revenue growth in FY26. Management also reiterated expectations for continued operating leverage, with a limited increase in OPEX despite significant revenue growth. As a result, mdxhealth expects to achieve a 10% adj. EBITDA run-rate by YE26. We reiterate our BUY and $ 6 TP.

02/27/26 February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch